Adiponectin, total anti-oxidant status, and high sensitivity C-reactive protein in Indonesian men with metabolic syndrome

  • Cynthia R. Sartika
  • Widjaja Lukito
  • Andi Wijaya
Keywords: adiponectin, hsCRP, total anti-oxidant status, metabolic syndrome
Abstract viewed: 584 times
PDF downloaded: 442 times


Aim To examine biochemical markers of adiponectin, total anti-oxidant status (TAOS) and high sensitvity C-reactive protein (hsCRP) in individuals with and without metabolic syndrome (MetS).

Methods A cross-sectional study on 36 non-MetS and 36 MetS subjects was undertaken in Jakarta. Measured indicators were adiponectin, TAOS and hsCRP, apart from weight, height, waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), and fasting blood glucose (FBG). Odds ratio (OR) of adiponectin, TAOS and hsCRP were calculated to assess risk for the development of MetS. Median values were determined as cut-offs to define high and low values of each parameter. Relationships between adiponectin, TAOS and hsCRP with WC were analyzed by using Spearman correlation analysis, and the contributions of all indicators to the development of MetS were analyzed by using logistic regression.

Results: Adiponectin dan hsCRP differed significantly between non MetS and MetS subjects (4.2 + 1.4 vs 3.1 + 1.0 ug/mL) dan (0.97 + 0.92 vs 3.35 + 3.43 mg/L) (p < 0.01), but no significant difference was found in TAOS (1.24 + 0.1 vs 1.28 + 0.2 mmol/L). Adiponectin associated negatively with WC (rs=  -0.436; p < 0.01), while TAOS and hsCRP associated positively with WC (rs= 0.286, p = 0.02 and rs= 0.597, p < 0.01). The odds ratios (ORs) of adiponectin and hsCRP for the development of MetS were 4 (p = 0.01) and ~6,8 (p < 0.01), respectively; while the risk of subjects with adiponectin-hsCRP ratio of ≤ 2.31 to develop MetS was 25 times (p < 0.01) those with adiponectin-hsCRP ratio > 2.31.

Conclusion The use of adiponectin-hsCRP ratio increases the predictive power for the occurrence of MetS by 4-6 times the predictive power of adiponectin or hsCRP alone. (Med J Indones 2009; 18: 262-8)


Download data is not yet available.


  1. Furukawa S, Fujita T, Shimabukuro M. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752–61.

  2. Semadji, G. The prevalence of the metabolic syndrome: Findings from the epidemiological study on obesity and its co-morbidities in Indonesian population. The 3rd National Obesity Symposium. Jakarta: Indonesian Society for the Study on Obesity, 2004.

  3. Grundy S. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 2005;25:2243–4.

  4. Stern PM, Williams K, Gonzales-Villalpando C, Hunt JK, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diab Care 2004;27:2676-81.

  5. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180–6.

  6. Reilly MP, Rader DJ. The Metabolic syndrome: more than the sum of its part? Circulation 2003;108:1546-51.

  7. Verma S, Buchanan MR, Anderson T. Endothelial function testing as a biomarker of vascular disease. Circulation 2003;108:2054-9.

  8. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Walsh K. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.

  9. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816-23.

  10. Xydakis, AM., Case, CC., Jones, PH., Hoogeveen, RC., Liu, M-Y., Smith, EO., Nelson, KW. and Ballantyne, CM. Adiponectin, infl ammation, and the expression of the metabolic syndrome in obese individuals: The impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004;89:2697-703.

  11. Alberti KG, Zimmet P, Shaw J. IDF epidemiology task force consensus group: The metabolic syndrome: a new worldwide defi nition. Lancet 2005;366:1059–62.

  12. Mojiminiyi OA, Abdella NA, Al Arouj M, Nakhi AB. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obes 2007;31:213–20

  13. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I. CRP and adiponectin and its oligomers in the metabolic syndrome: Evaluation of new laboratory-based biomarkers. Am J Clin Pathol 2008;129:815–22.

  14. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998;44:1309–15.

  15. Koracevic D, Koracevic G, Djordjevic V, Andredjevic S, Cosic V. Method for measurement of antioxidant activity in human fl uids. J Clin Pathol 2001;54:356-61.

  16. Psotová J, Zahálková J, Hrbáč J, Šimánek V, Bartek J. Determination of total antioxidant capacity in plasma by cyclic voltammetry. two case reports. Biomed Papers 2001;145:81–3.

  17. Wang CC, Chu CY, Chu KO, Choy KW, Khaw KS, Rogers MS, et al. Trolox-equivalent antioxidant capacity assay versus oxygen radical absorbance capacity assay in plasma. Clin Chem 2004;50:952-4.

  18. Szmitko PE, Wang C-H, Weisel RD, Almeida JR, Anderson TJ, Verma S. New marker of inflammation and endothelial cell activation: Part I. Circulation 2003;108:1917-23.

How to Cite
Sartika CR, Lukito W, Wijaya A. Adiponectin, total anti-oxidant status, and high sensitivity C-reactive protein in Indonesian men with metabolic syndrome. Med J Indones [Internet]. 2009Nov.1 [cited 2024Jul.21];18(4):262-8. Available from:
Clinical Research

Most read articles by the same author(s)